The EMA's practical guide to what happens when a company applies to take part in the adaptive licensing experiment.
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Memo Therapeutics is sharpening its focus on its lead antibody Potravitug, for BK polyomavirus (BKPyV) in kidney transplant patients as it prepares for Phase III trials and doubles down on patient engagement.
Chinese medtechs are expanding rapidly worldwide, but gaining market access within China itself – poised to become the world’s largest medtech market – is proving to be a very different challenge.
The rapid growth of Chinese biopharmas has led to increased dealmaking with the US and Europe, but that could be stifled by a potential new Trump Administration policy.
China has rapidly expanded its clinical trial footprint since 2015, driven by regulatory reforms and increased investment in pharma R&D. By 2023, it matched the US in trial volume. Oncology leads, but biologics are leading in momentum.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recursion recently announced the completion of a $30m microglia map and named Najat Khan as CEO, replacing co-founder Chris Gibson.
Patient advocacy organizations are transforming gene therapy development by funding research, de-risking programs and driving ultra-rare disease treatments from concept to clinic at unprecedented speed.
